FOR AUTHORS
Search
Search Results
##search.searchResults.foundPlural##
-
PO-21 | Evaluating the impact of anti-CGRP monoclonal antibodies on retinal features in migraine patients: a retrospective optical coherence tomography study Chiara Serafini,1 Massimo Cesareo,2 Alessio Martucci,2 Marco Lombardo,2 Vittoria Carla D’Agostino,1 Alessandro Stefani,3 Carlo Nucci,2 Nicola Biagio Mercuri,1,3 Maria Albanese1,3 | 1Regional Referral Headache Center, Neurology Unit, Tor Vergata University Hospital, Rome, Italy 2Ophthalmology Unit, Department of Experimental Medicine, University of Rome “Tor Vergata”, Rome; 3Department of Systems Medicine, University of Rome “Tor Vergata”, Rome, Italy
49 -
OC-13 | Monoclonal antibodies targeting CGRP differently affect sleep and psychiatric comorbidities in reproductive and postmenopausal chronic migraine women Giulia Procopio, Letizia Curto, Antonia Di Chirico, Leonardo Troilo, Gabriele Siciliano, Filippo Baldacci, Sara Gori | Neurology Unit, Department of Clinical and Experimental Medicine, University of Pisa-AOUP, Pisa, Italy
49 -
PO-67 | Investigating plasma neurofilament light chain levels in patients with migraine: a cross-sectional study Elisa Maria Piella,1 Alberto Mario Chiarandon,1 Silvia Boschi,1 Fausto Roveta,1 Lucrezia Bonino,1 Giulia Gioiello,2 Giulia Montesano,2 Giulio Mengozzi,2 Innocenzo Rainero,1,3 Elisa Rubino1,3 | 1Department of Neuroscience “Rita Levi Montalcini”, University of Turin, Turin, Italy; 2Clinical Biochemistry Laboratory “Baldi e Riberi”, A.O.U. Città della Salute e della Scienza di Torino, Turin, Italy; 3Headache Center, Department of Neuroscience and Mental Health, AOU Città della Salute e della Scienza di Torino, Turin, Italy
18 -
PO-44 | Effectiveness of fremanezumab as preventive treatment of migraine up to 24 months: response rates from the Italian analysis of the PEARL study Alberto Doretti,1 Anna Ambrosini,2 Simone Braca,3 Florindo D’Onofrio,4 Elisa Maria Piella,5 Pinar Kokturk,6 Rosario Iannacchero7 | 1Department of Neurology-Laboratory of Neuroscience, IRCCS, Istituto Auxologico Italiano, Milan, Italy; 2Mediterranean Neurological Institute NEUROMED IRCCS, Pozzilli (IS), Italy; 3Headache Centre, University of Naples “Federico II”, Naples, Italy; 4UOSD Stroke Unit, S.G. Moscati Hospital, Avellino, Italy; 5Neurosciences Department, University of Turin, Turin, Italy; 6Teva Netherlands B.V., Haarlem, The Netherlands; 7Department of Neurology, Headache Center, Regional Hospital “Pugliese-Ciaccio”, Catanzaro, Italy
16 -
PO-22 | Impact of sleep disorders on anti-CGRP monoclonal antibodies treatment response in migraine: a cross-sectional study Costanza Sottani,1 Valerio Brunetti,1,2 Fabiana Cerulli,1 Claudia Garattini,4 Gianluca Avino,5 Paolo Calabresi,1,3 Catello Vollono1,4 | 1Università Cattolica del Sacro Cuore, Dipartimento di Neuroscienze, Rome; 2Stroke Unit, Fondazione Policlinico Agostino Gemelli IRCSS, Rome; 3UOC Neurologia, Fondazione Policlinico Agostino Gemelli IRCSS, Rome; 4UOC Neurofisiopatologia, Fondazione Policlinico Agostino Gemelli IRCSS, Rome; 5Unità di Neurologia, Ospedale Santo Stefano, Prato, Italy
13 -
PO-75 | Network meta-analysis comparing efficacy and safety outcomes of atogepant, rimegepant, and galcanezumab in patients with episodic migraine after including CHALLENGE-MIG Trial Jessica Ailani,1 Pranav Gandhi,2 Anjana Lalla,2 Peter McAllister,3 Tanya Bilchik,4 Stephanie Nahas,5 David Rowe,6 Cristiano Piron,6 Kari Kelton,6 Raffaello Masselli*, Rashmi Halker Singh7 | 1MedStar Health, Washington DC, USA; 2AbbVie, North Chicago, IL, USA; 3New England Institute for Neurology and Headache, Stamford, CT USA; 4Department of Neurology, Yale School of Medicine, New Haven, CT, USA; 5Department of Neurology, Thomas Jefferson University, Philadelphia, PA USA; 6Medical Decision Modeling Inc., Indianapolis, IN, USA; 7Mayo Clinic, Phoenix, AZ, USA *Abbvie Srl, Rome, Italy. This individual has been added to this publication author by-line, with the permission of the original authors, for the express purpose of conducting the presentation at a local congress or in a local language. He did not contribute to the content of the publication.
56 -
PO-54 | Patient perspectives on physiotherapy interventions for migraine: a pre- and post-intervention qualitative study Zhiqi Liang,1 Caitlin Scott,1 Felix Cabrera Manrique,1 Sumin Kim,1 Chun Shun Lee,1 Bixiang Cheng,1 Chun Yiu Kwok,1 Matteo Castaldo2 | 1University of Queensland; 2Parma University, Italy
12 -
PO-62 | Preventive migraine treatment in patients under 25: a 24-month observational study on adherence, therapeutic switching, and prescription determinant factors Marilena Marcosano,1 Nicoletta Brunelli,1 Luisa Fofi,1 Laura Papetti,2 Fabiana Ursitti,2 Massimiliano Valeriani,2 Fabrizio Vernieri,1 Claudia Altamura1 | 1Headache and Neurosonology Unit, Fondazione Policlinico Campus Biomedico di Rome, Rome, Italy; 2Developmental Neurology, Bambino Gesù Children Hospital, IRCCS, Rome, Italy
9 -
PO-13 | HD-EEG Delta connectivity rapidly alters after one month of atogepant in migraine patients Maria Albanese,1,2 Matteo Conti,1 Silvio Bagetta,1 Federico Carparelli,2 Vittoria Carla D’Agostino,2 Fabio Placidi,1,2 Alessandro Stefani,1,2 Nicola Biagio Mercuri,1-3 | 1Department of Systems Medicine, University of Rome Tor Vergata, Rome; 2Neurology Unit, Tor Vergata University Hospital, Rome; 3IRCCS Santa Lucia Foundation, Rome, Italy
50 -
PO-55 | What patients want: a qualitative study on an information resource on migraine Matteo Castaldo,1 Zhiqi Liang,2 Gina Williams,2 Shayne Watson,2 Caitlyn Haynes,2 Zoe Diamond2 | 1Parma University; 2University of Queensland
11 -
PO-31 | Could lamotrigine represent an effective treatment strategy in patients with migraine with aura? An observational study M. Marziani, M. Silvestro, I. Orologio, L. Tartaglione, F.M. Chianese, A. Tessitore, A. Russo | Headache Centre, Department of Advanced Medical and Surgical Sciences, University of Campania “Luigi Vanvitelli”, Italy
31 -
PO-77 | Real-world evidence of Atogepant efficacy in patients unresponsive to anti-CGRP monoclonals Matteo Cortinovis, Marco Bolchini, Paola Zavarise, Giulia Campana, Giorgio Dalla Volta | Headache Center, Istituto Clinico Città di Brescia, Gruppo San Donato, Brescia, Italy
39 -
PO-14 | Pain catastrophizing in chronic migraine patients receiving eptinezumab treatment Alessandra Parisi,1 Licia Grazzi,1 Alberto Raggi,2 Giulia Regonesi,1 Montisano Danilo Antonio1 | 1Headache Center, Fondazione IRCCS Istituto Neurologico Carlo Besta, Milano; 2Neurology, Public Health and Disability Unit, Fondazione IRCCS Istituto Neurologico Carlo Besta, Milano, Italy
56 -
PO-32 | Post-traumatic painful trigeminal neuropathy (13.1.2.3 - ICHD-3) following misguided gamma knife surgery: a case of diagnostic oversight with lasting consequences Marta Lioi,1 Laura Marino,1 Michele Trimboli2 | 1Department of Neurology, Magna Graecia University, Catanzaro, Italy; 2Institute of Neurology, AOU Renato Dulbecco, Catanzaro, Italy
32 -
PO-47 | Systemic ozone treatment in chronic migraine: a focus on disability reduction and medication use Sergio Sorrenti,1,2 Matteo Ciuffreda,1 Emanuele Pisello,1 Luca Brugiaferri,2 Azzurra Federici,2 Cristiano Piangatelli,3 Dario Galante4 | 1U.O.C. Anestesia Rianimazione Terapia del Dolore, AST Ancona, Fabriano (AN), Italy; 2Scuola di Specializzazione in Anestesia Rianimazione, Terapia Intensiva e del Dolore, UNIVPM, Ancona, Italy; 3Direttore U.O.C. Anestesia Rianimazione Terapia del Dolore, AST Ancona, Fabriano (AN), Italy; 4Direttore U.O.C. Anestesia e Rianimazione, Cerignola (FG), Italy
11 -
PO-25 | Antiepileptic medication in PRRT2 familial hemiplegic migraine: a case report L. Bartole, A. Granato, G. Garascia, P. Manganotti | Clinical Unit of Neurology, Headache Centre, Department of Medicine, Surgery and Health Sciences, University of Trieste, Italy
37 -
Manual trigger point treatment in migraine management: a scope review
582PDF: 179SUPPLEMENTARY: 93 -
PO-78 | No changes in blood pressure assessed with the 24-hour Holter monitoring in patients treated with anti-CGRP monoclonal antibodies: a prospective observational study (SAFHYPER) Flavia Lo Castro,1 Niccolò Bonini,2 Luigi Francesco Iannone,1,3 Alberto Boccalini,1 Daria Brovia,1 Luca Pani,1,3 Giuseppe Boriani,2,3 Simona Guerzoni1 | 1Digital and Predictive Medicine, Pharmacology and Clinical Metabolic Toxicology-Headache Center and Drug Abuse-Laboratory of Clinical Pharmacology and Pharmacogenomics, AOU Policlinico di Modena, Modena, Italy; 2Cardiology Division, AOU Policlinico di Modena, Modena, Italy; 3Department of Biomedical, Metabolic, and Neural Science, University of Modena and Reggio Emilia, Modena, Italy
39 -
PO-20 | Phenotypic description of a multigenerational family with PRRT2 gene mutation: a case series of six members affected by hemiplegic migraine and paroxysmal events Fabiana Cerulli,1 Costanza Sottani,1 Giulia Di Lazzaro,1,2 Paolo Calabresi,1,2 Anna Rita Bentivoglio,1,2 Catello Vollono1,3 | 1Dipartimento Universitario di Neuroscienze, Università Cattolica del Sacro Cuore, Rome; 2UOC Neurologia, Fondazione Policlinico Universitario "A. Gemelli" IRCCS, Rome, Italy; 3Neurofisiopatologia, Dipartimento di Scienze dell'invecchiamento, Neurologiche, Ortopediche e della Testa-Collo, Fondazione Policlinico Universitario "A. Gemelli" IRCCS, Rome, Italy
43 -
PO-57 | Early treatment with atogepant improves sleep quality without sleep-related adverse events: a prospective observational study Alberto Boccalini,1 Luigi Francesco Iannone,1,2* Flavia Lo Castro,1 Daria Brovia,1 Marina Romozzi,3,4 Fabrizio Vernieri,5,6 Claudia Altamura,5,6 Simona Guerzoni1 | 1Digital and Predictive Medicine, Pharmacology and Clinical Metabolic Toxicology-Headache Center and Drug Abuse-Laboratory of Clinical Pharmacology and Pharmacogenomics, AOU Policlinico di Modena, Modena, Italy; 2Department of Biomedical, Metabolic, and Neural Science, University of Modena and Reggio Emilia, Modena, Italy; 3Dipartimento Universitario di Neuroscienze, Università Cattolica del Sacro Cuore, Rome, Italy; 4Neurologia, Dipartimento di neuroscienze, Organi di Senso e Torace, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome, Italy; 5Headache Unit, Fondazione Policlinico Universitario Campus Bio-Medico, Roma, Italy; 6Università Campus Bio-Medico di Roma, Italy
13 -
PO-33 | Visual hallucinations: a non-unique symptom Francesca Traccitto, Giada Giuliani, Davide Chiffi, Chiara Zilli, Mariangela Fratino, Marta Altieri | Department of Human Neuroscience, Sapienza University of Rome, Rome, Italy
10 -
PO-48 | Flunarizine for preventive treatment of hemiplegic migraine during pregnancy: a case report Andrea Burgalassi,1 Antonio Munafò,2 Francesco De Cesaris,1 Giulia Vigani,2 Alberto Chiarugi1,2 | 1Headache Center and Clinical Pharmacology Unit, Careggi University Hospital, Florence, Italy; 2Section of Clinical Pharmacology and Oncology, Department of Health Sciences, University of Florence, Florence, Italy
12 -
PO-72 | Stigma in migraine: preliminary results from the “Studio Emicrania Maugeri” Project Luca Giani, Christian Lunetta | Istituti Clinici Scientifici Maugeri IRCCS, Neurological Rehabilitation Unit of Milano Institute, Milan, Italy
13 -
PO-92 QZU® (Kudzu e.s.: 200 mg of which Isoflavones: 80 mg and Puerarin: 60 mg; ComplexZyme vegan®: 40 mg) in the prophylaxys of migraine without aura: a retrospective observational study Ennio Pucci,1 Ludovica Pucci,2 Alberto Vercesi3 | 1Department of Nervous System and Behavioral Sciences, University of Pavia; 2Nutritional biologist, Master in Nutritional and Clinical Dietetics, University of Pavia, Italy; 3Scientific Advisor
71 -
OC-05 | Mid-term effectiveness and tolerability of atogepant in the prevention of migraine: a real life, prospective, multicentric study (the STAR study) Fabrizio Vernieri,1 Luigi Francesco Iannone,2,3 Gabriele Sebastianelli,4 Flavia Lo Castro,2, Federico De Santis,5 Michele Corrado,6 Marilena Marcosano,1 Raffaele Ornello,5 Licia Grazzi,7 Danilo Antonio Montisano,7 Francesco De Cesaris,8 Antonio Munafò,8 Gianluca Avino,9 Michele Trimboli,10 Maria Albanese,11 Antonio Russo,12 Giorgio Dalla Volta,13 Marina Romozzi,14 Paola Merlo,15 Maria Pia Prudenzano,16 Maria Rosaria Valente,17 Innocenzo Rainero,18 Giada Giuliani,19 Luisa Fofi,1 Alberto Doretti,20 Gloria Vaghi,6 Francesca Pistoia,5 Delfina Ferrandi,21 Stefania Battistini,22 Simona Sacco,5 Simona Guerzoni,2 Claudia Altamura1 on behalf of the Italian Headache Registry (RICe) Study Group | 1Fondazione Policlinico Campus Bio-Medico, Roma; 2AOU Policlinico di Modena; 3Università di Modena e Reggio Emilia. 4Sapienza University of Rome Polo Pontino, Latina; 5University of L’Aquila; 6University of Pavia, Pavia, Italy and IRCCS Mondino Foundation, Pavia; 7IRCCS Istituto Neurologico Carlo Besta, Milano; 8AOU Careggi, Firenze; 9SOC Neurologia, Ospedale di Prato, Prato; 10Azienda Ospedaliera-universitaria "Renato Dulbecco", Catanzaro; 11Università Roma Tor Vergata, Roma; 12Università della Campania "Luigi Vanvitelli", Napoli; 13U.O Neurologia, Istituto Clinico Città di Brescia, Gruppo San Donato, Brescia; 14Fondazione Policlinico Universitario A. Gemelli IRCCS, Università Cattolica del Sacro Cuore, Roma; 15UO di Neurologia, Humanitas Gavazzeni, Bergamo; 16Clinica Neurologica "L. Amaducci", Azienda Ospedaliero-Universitaria Consorziale di Bari; 17Dipartimento di Neuroscienze, Azienda Sanitaria Universitaria Integrata di Udine; 18Dipartimento di Neuroscienze, Città della Salute e della Scienza di Torino; 19Centro per la diagnosi e terapia delle cefalee, Policlinico Umberto I, Roma; 20IRCCS Istituto Auxologico Italiano, Milano; 21AOU Alessandria; 22University of Siena, Siena, Italy
13